Advertisement

Clinical and Experimental Nephrology

, Volume 23, Issue 5, pp 597–605 | Cite as

Low-energy extracorporeal shock wave ameliorates ischemic acute kidney injury in rats

  • Mai Yoshida
  • Takashi NakamichiEmail author
  • Takefumi Mori
  • Kenta Ito
  • Hiroaki Shimokawa
  • Sadayoshi Ito
Original article

Abstract

Background

Low-energy extracorporeal shock wave (SW) improves ventricular function in ischemic cardiomyopathy through the upregulation of vascular endothelial growth factor (VEGF). VEGF is known to play important roles in acute kidney injury (AKI), and the present study investigates the efficacy of SW for AKI by renal ischemia–reperfusion (I/R) injury.

Methods

Male 8-week-old Sprague–Dawley rats were divided into the following groups: SW-treated I/R group (I/R-SW), untreated I/R group (I/R), and Sham group. To induce I/R, the left renal pedicles were clamped for 45 min. The I/R-SW group was treated with SW to both kidneys on the immediate postoperative period (day 0), days 1, 2, 7, 8, 9, 14, 15, and 16. Rats were killed on day 2 and day 20 to determine histology, renal function, and Vegf family mRNA expression.

Results

Plasma creatinine on day 2 was significantly lower in the I/R-SW group than in the I/R group. Light microscopy revealed significantly lower tubular injury scores for the outer medulla in the I/R-SW group than in the I/R group. Podoplanin-positive lymphatic vessels were significantly increased in the left (affected side) outer medulla in the I/R-SW group on day 20. The expression levels of Vegf in the right (intact side) cortex were significantly higher in the I/R-SW group than in the I/R group on day 2.

Conclusion

Shock wave ameliorated renal tubular injury and renal function in AKI model, through the stimulation of Vegf family expression and lymphangiogenesis. SW may be effective as a non-invasive treatment for ischemic AKI.

Keywords

Ischemic acute kidney injury Shock wave Vascular endothelial growth factor Lymphangiogenesis 

Notes

Compliance with ethical standards

Conflict of interest

The authors have declared that no conflicts of interest exist.

Ethical approval

The protocols of the present study were approved by the ethics committee on animal experiments of Tohoku University (No. 2011-303).

Informed consent

This section is not applicable to this study.

References

  1. 1.
    Yasuda H, Kato A, Fujigaki Y, Hishida A, Shizuoka Kidney Disease Study G. Incidence and clinical outcomes of acute kidney injury requiring renal replacement therapy in Japan. Ther Apher Dial. 2010;14(6):541–6.  https://doi.org/10.1111/j.1744-9987.2010.00826.x.CrossRefGoogle Scholar
  2. 2.
    Schetz M, Gunst J, De Vlieger G, Van den Berghe G. Recovery from AKI in the critically ill: potential confounders in the evaluation. Intensive Care Med. 2015;41(9):1648–57.  https://doi.org/10.1007/s00134-015-3946-3.CrossRefGoogle Scholar
  3. 3.
    Chade AR. VEGF: potential therapy for renal regeneration. F1000. Med Rep. 2012;4:1.  https://doi.org/10.3410/M4-1.Google Scholar
  4. 4.
    Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol. 2010;8(1):122–8.CrossRefGoogle Scholar
  5. 5.
    Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe K, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004;110(19):3055–61.  https://doi.org/10.1161/01.CIR.0000148849.51177.97.CrossRefGoogle Scholar
  6. 6.
    Fukumoto Y, Ito A, Uwatoku T, Matoba T, Kishi T, Tanaka H, et al. Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease. Coron Artery Dis. 2006;17(1):63–70.CrossRefGoogle Scholar
  7. 7.
    Kikuchi Y, Ito K, Ito Y, Shiroto T, Tsuburaya R, Aizawa K, et al. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris. Circ J. 2010;74(3):589–91.CrossRefGoogle Scholar
  8. 8.
    Serizawa F, Ito K, Kawamura K, Tsuchida K, Hamada Y, Zukeran T, et al. Extracorporeal shock wave therapy improves the walking ability of patients with peripheral artery disease and intermittent claudication. Circ J. 2012;76(6):1486–93.CrossRefGoogle Scholar
  9. 9.
    Abe Y, Ito K, Hao K, Shindo T, Ogata T, Kagaya Y, et al. Extracorporeal low-energy shock-wave therapy exerts anti-inflammatory effects in a rat model of acute myocardial infarction. Circ J. 2014;78(12):2915–25.CrossRefGoogle Scholar
  10. 10.
    Ito Y, Ito K, Shiroto T, Tsuburaya R, Yi GJ, Takeda M, et al. Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. Coron Artery Dis. 2010;21(5):304–11.CrossRefGoogle Scholar
  11. 11.
    Uwatoku T, Ito K, Abe K, Oi K, Hizume T, Sunagawa K, et al. Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs. Coron Artery Dis. 2007;18(5):397–404.  https://doi.org/10.1097/MCA.0b013e328089f19b.CrossRefGoogle Scholar
  12. 12.
    Serizawa F, Ito K, Matsubara M, Sato A, Shimokawa H, Satomi S. Extracorporeal shock wave therapy induces therapeutic lymphangiogenesis in a rat model of secondary lymphoedema. Eur J Vasc Endovasc Surg. 2011;42(2):254–60.  https://doi.org/10.1016/j.ejvs.2011.02.029.CrossRefGoogle Scholar
  13. 13.
    Yamaya S, Ozawa H, Kanno H, Kishimoto KN, Sekiguchi A, Tateda S, et al. Low-energy extracorporeal shock wave therapy promotes vascular endothelial growth factor expression and improves locomotor recovery after spinal cord injury. J Neurosurg. 2014;121(6):1514–25.  https://doi.org/10.3171/2014.8.JNS132562.CrossRefGoogle Scholar
  14. 14.
    Gigliotti JC, Huang L, Ye H, Bajwa A, Chattrabhuti K, Lee S, et al. Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol. 2013;24(9):1451–60.  https://doi.org/10.1681/asn.2013010084.CrossRefGoogle Scholar
  15. 15.
    Gigliotti JC, Huang L, Bajwa A, Ye H, Mace EH, Hossack JA, et al. Ultrasound modulates the splenic neuroimmune axis in attenuating AKI. J Am Soc Nephrol. 2015;26(10):2470–81.  https://doi.org/10.1681/asn.2014080769.CrossRefGoogle Scholar
  16. 16.
    Roelofs JJ, Rouschop KM, Leemans JC, Claessen N, de Boer AM, Frederiks WM, et al. Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. J Am Soc Nephrol. 2006;17(1):131–40.  https://doi.org/10.1681/ASN.2005010089.CrossRefGoogle Scholar
  17. 17.
    Sakamoto I, Ito Y, Mizuno M, Suzuki Y, Sawai A, Tanaka A, et al. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int. 2009;75(8):828–38.  https://doi.org/10.1038/ki.2008.661.CrossRefGoogle Scholar
  18. 18.
    Apfel RE. Acoustic cavitation: a possible consequence of biomedical uses of ultrasound. Br J Cancer Suppl. 1982;5:140–6.Google Scholar
  19. 19.
    Maisonhaute E, Prado C, White PC, Compton RG. Surface acoustic cavitation understood via nanosecond electrochemistry. Part III: shear stress in ultrasonic cleaning. Ultrason Sonochem. 2002;9(6):297–303.CrossRefGoogle Scholar
  20. 20.
    Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003–17.  https://doi.org/10.1111/j.1523-1755.2004.00621.x.CrossRefGoogle Scholar
  21. 21.
    Sun D, Wang Y, Liu C, Zhou X, Li X, Xiao A. Effects of nitric oxide on renal interstitial fibrosis in rats with unilateral ureteral obstruction. Life Sci. 2012;90(23–24):900–9.  https://doi.org/10.1016/j.lfs.2012.04.018.CrossRefGoogle Scholar
  22. 22.
    Leonard EC, Friedrich JL, Basile DP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Ren Physiol. 2008;295(6):F1648-57.  https://doi.org/10.1152/ajprenal.00099.2008.CrossRefGoogle Scholar
  23. 23.
    Breen EC. VEGF in biological control. J Cell Biochem. 2007;102(6):1358–67.  https://doi.org/10.1002/jcb.21579.CrossRefGoogle Scholar
  24. 24.
    Matsui K, Nagy-Bojarsky K, Laakkonen P, Krieger S, Mechtler K, Uchida S, et al. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopeptidase p and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J Am Soc Nephrol. 2003;14(8):1981–9.CrossRefGoogle Scholar
  25. 25.
    Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. Fluid balance and acute kidney injury. Nat Rev Nephrol. 2010;6(2):107–15.  https://doi.org/10.1038/nrneph.2009.213.CrossRefGoogle Scholar
  26. 26.
    Prowle JR, Kirwan CJ, Bellomo R. Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol. 2014;10(1):37–47.  https://doi.org/10.1038/nrneph.2013.232.CrossRefGoogle Scholar
  27. 27.
    Bi LY, Zhao DA, Yang DS, Guo JG, Liang B, Zhang RX, et al. Effects of autologous SCF- and G-CSF-mobilized bone marrow stem cells on hypoxia-inducible factor-1 in rats with ischemia-reperfusion renal injury. Genet Mol Res. 2015;14(2):4102–12.  https://doi.org/10.4238/2015.April.27.25.CrossRefGoogle Scholar
  28. 28.
    Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR. Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Ren Physiol. 2008;294(4):F928-36.  https://doi.org/10.1152/ajprenal.00596.2007.CrossRefGoogle Scholar
  29. 29.
    Labanaris AP, Kuhn R, Schott GE, Zugor V. Perirenal hematomas induced by extracorporeal shock wave lithotripsy (ESWL). Ther Manag Sci World J. 2007;7:1563–6.  https://doi.org/10.1100/tsw.2007.236.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2019

Authors and Affiliations

  1. 1.Division of Nephrology, Endocrinology and Vascular MedicineTohoku University Graduate School of MedicineSendaiJapan
  2. 2.Department of Cardiovascular MedicineTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations